Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (371-380 of 584) with videos related to

Pageof 59
Sort By:
American Journal of Hematology|June 20, 2014
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemiaCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Theranostics|June 29, 2026
Ultrasound targeted fatty acid nitroalkene-containing lipid nanoparticles attenuate inflammation and reverse myocardial fibrosisMuhammad W Amjad, Soheb A Mohammed, Marco Fazzari, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 16, 2017
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive LeukemiasJorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, et al.
Epidemiology and Infection|August 3, 2013
A relationship between acute respiratory illnesses and weatherA Costilla-Esquivel, F Corona-Villavicencio, J G Velasco-Castañón, et al.
Leukemia|April 9, 2020
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized studyJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Blood Cancer Journal|September 8, 2018
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinibOliver Ottmann, Giuseppe Saglio, Jane F Apperley, et al.
Cardio-Oncology (London, England)|May 23, 2026
Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
Blood|April 7, 2011
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibJorge E Cortes, Andreas Hochhaus, Philipp D le Coutre, et al.
Pageof 59

Showing results (371-380 of 584) with videos related to

Sort By:
Pageof 59
American Journal of Hematology|June 20, 2014
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemiaCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Theranostics|June 29, 2026
Ultrasound targeted fatty acid nitroalkene-containing lipid nanoparticles attenuate inflammation and reverse myocardial fibrosisMuhammad W Amjad, Soheb A Mohammed, Marco Fazzari, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 16, 2017
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive LeukemiasJorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, et al.
Epidemiology and Infection|August 3, 2013
A relationship between acute respiratory illnesses and weatherA Costilla-Esquivel, F Corona-Villavicencio, J G Velasco-Castañón, et al.
Leukemia|April 9, 2020
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized studyJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Blood Cancer Journal|September 8, 2018
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinibOliver Ottmann, Giuseppe Saglio, Jane F Apperley, et al.
Cardio-Oncology (London, England)|May 23, 2026
Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysisJoshua D Mitchell, Michael Pfeiffer, John Boehmer, et al.
Blood|April 7, 2011
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibJorge E Cortes, Andreas Hochhaus, Philipp D le Coutre, et al.
Pageof 59